Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) – Stock analysts at Zacks Research lifted their Q4 2026 earnings per share estimates for Corcept Therapeutics in a research report issued on Wednesday, September 16th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of $0.68 for the quarter, up from their previous estimate of $0.62. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $2.02 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2027 earnings at $0.78 EPS, Q4 2027 earnings at $0.65 EPS, FY2027 earnings at $2.05 EPS and FY2028 earnings at $4.31 EPS.
A number of other analysts have also weighed in on CORT. UBS Group set a $135.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, May 28th. Piper Sandler reaffirmed an “overweight” rating and set a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. Weiss Ratings downgraded Corcept Therapeutics from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 8th. Canaccord Genuity Group raised their price target on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Finally, Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $138.17.
Corcept Therapeutics Trading Up 0.9%
CORT stock opened at $111.81 on Thursday. The stock has a market cap of $12.09 billion, a PE ratio of 266.22 and a beta of 0.45. Corcept Therapeutics has a 12 month low of $28.66 and a 12 month high of $126.38. The company has a 50-day moving average price of $107.76 and a 200 day moving average price of $74.40.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.34. The firm had revenue of $256.15 million for the quarter, compared to the consensus estimate of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The company’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 EPS.
Insider Activity at Corcept Therapeutics
In other news, Director Kimberly Park sold 26,685 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $122.55, for a total transaction of $3,270,246.75. Following the completion of the sale, the director owned 30,000 shares of the company’s stock, valued at approximately $3,676,500. The trade was a 47.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James N. Wilson sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $110.69, for a total value of $1,106,900.00. Following the completion of the sale, the director owned 1,064,543 shares of the company’s stock, valued at $117,834,264.67. The trade was a 0.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 446,119 shares of company stock worth $50,644,753 over the last ninety days. 20.70% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Corcept Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Sequoia Financial Advisors LLC bought a new position in shares of Corcept Therapeutics during the 2nd quarter worth $645,000. Tidal Investments LLC lifted its stake in Corcept Therapeutics by 9.2% in the second quarter. Tidal Investments LLC now owns 24,218 shares of the biotechnology company’s stock worth $2,106,000 after acquiring an additional 2,039 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Corcept Therapeutics in the second quarter worth about $558,000. NewEdge Advisors LLC grew its holdings in Corcept Therapeutics by 17.9% during the 2nd quarter. NewEdge Advisors LLC now owns 11,041 shares of the biotechnology company’s stock worth $960,000 after acquiring an additional 1,677 shares in the last quarter. Finally, IFP Advisors Inc grew its holdings in Corcept Therapeutics by 568.4% during the 2nd quarter. IFP Advisors Inc now owns 909 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 773 shares in the last quarter. 93.61% of the stock is owned by institutional investors.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.
Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.
Read More
- Five stocks we like better than Corcept Therapeutics
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
